The in vivo performance of multiparticulate sustained-release diltiazem preparations [HER-SR(A,B,C)] coated with water-insoluble polymer (ethylcellulose), to control the in vitro dissolution rate, was evaluated in dogs. With a decrease in dissolution rate, HER-SR maintained sustained-release charact
Pharmacokinetics of an oral sustained-release diltiazem preparation
โ Scribed by Kazuo Murata; Hiroshi Yamahara; Masao Kobayashi; Kazuo Noda; Masayoshi Smejima
- Publisher
- John Wiley and Sons
- Year
- 1989
- Tongue
- English
- Weight
- 363 KB
- Volume
- 78
- Category
- Article
- ISSN
- 0022-3549
No coin nor oath required. For personal study only.
โฆ Synopsis
The pharmacokinetics of a new oral sustained-release diltiazem preparation (HER-SR,QD) was investigated in dogs and humans. The mean plasma diltiazem concentration in dogs after oral administration of HER-SR showed a prolonged plasma concentration and a double peak. The bioavailability of HER-SR compared with that of a conventional diltiazem preparation (HER) in dogs was -80%, a value that is relatively close to that of humans. The plasma diltiazem concentrations with a double peak in dogs were analyzed using multifraction absorption models. The HER-SR preparation was apparently divided into two fractions (14.3 and 85.7 mg) in the gastrointestinal tract, each fraction was absorbed at rate constants of 4.560 and 0.1 52 h-', respectively, and the lag time of the slow-release component was 8.3 h. The plasma diltiazem concentration data in humans after repetitive oral administration of HER-SR were also analyzed using multifraction absorption models. The initial amount of the fast-and slow-release components were 14.8 and 85.2 mg, respectively. The absorption rate constants were 0.730 h-' for the fast-release component and 0.060 h-' for the slow-release component. The lag time of absorption for the slow-release component was 6.0 h. The pharmacokinetic parameters were close to those obtained in dogs except for K, , and VdMF. The results confirm that HER-SR has desirable pharmacokinetic characteristics as judged from the simulated plasma diltiazem concentration and the peak-to-trough fluctuation (fluctuation parameters) calculated using the simulated plasma diltiazem concentration. In addition, population pharmacokinetics of HER-SR after repetitive oral administration was examined in humans.
๐ SIMILAR VOLUMES
The pharmacokinetics of two new sustained-release (SR) products of diltiazem, Dilapress 120 mg tablets and Dilapress 240 mg tablets, was analysed and characterized in three different studies, in comparison to the following diltiazem SR formulations: Cardizem Retard, Cardizem SR, and Cardizem CD. Dil
Micro-porous ethylcellulose (EC) membrane capsules were prepared by dissolving polyvinylalcohol (PVA) particles from membranes which were made of a mixture of EC (a water-insoluble polymer). The pore size was approximately 400 mm. Since the dissolution rate of theophylline from the micro-porous EC m
## Abstract Physiological changes occurring in diabetes mellitus patients could alter the pharmacokinetics of drugs used to treat hypertension resulting from diabetic complications. Hence, the pharmacokinetics of diltiazem (DTZ) and its metabolite, desacetyldiltiazem (DAD), were investigated after
The kinetics and negative dromotropic action of intravenous (1 mg kg-') and oral (5 mg kg-') diltiazem were studied in dogs after acute doses, after treatment for 3 days with oral diltiazem (5 mg kg-I, t.i.d.), and after 3 days' treatment with oral diltiazem (5 mg kg-' t.i.d.) and cimetidine (200mg